Answers are grounded in this paper and cite their sources.
The occurrence of radiation necrosis to the extravasation of therapeutic radionuclide-yttrium-90-ibritumomab tiuxetan-is described, as well as the subsequent steps taken to both address the occurrence and to prevent the re-occurrence of such an adverse event. Published reports on the extravasation of diagnostic and therapeutic radionuclides are reviewed, as are prevention and treatment protocols.
No takes yet. Share an insight, caveat, or question.
Williams et al. (2006) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: